347 related articles for article (PubMed ID: 35688553)
1. Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression.
Lv T; Xiong X; Yan W; Liu M; Xu H; He Q
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688553
[TBL] [Abstract][Full Text] [Related]
2. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
3. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
[TBL] [Abstract][Full Text] [Related]
4. SRSF10 facilitates HCC growth and metastasis by suppressing CD8
Luo X; Zhang Z; Li S; Wang Y; Sun M; Hu D; Jiang J; Wang Y; Ji X; Chen X; Zhang B; Liang H; Li Y; Liu B; Xu X; Wang S; Xu S; Nie Y; Wu K; Fan D; Liu D; Huang W; Xia L
Int Immunopharmacol; 2024 Jan; 127():111376. PubMed ID: 38113691
[TBL] [Abstract][Full Text] [Related]
5. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
[TBL] [Abstract][Full Text] [Related]
6. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
[TBL] [Abstract][Full Text] [Related]
7. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
[TBL] [Abstract][Full Text] [Related]
8. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
[TBL] [Abstract][Full Text] [Related]
9. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
10. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
[TBL] [Abstract][Full Text] [Related]
11. Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC.
Li K; Gong Y; Qiu D; Tang H; Zhang J; Yuan Z; Huang Y; Qin Y; Ye L; Yang Y
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002188
[TBL] [Abstract][Full Text] [Related]
12. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
13. Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade.
Jiang Y; Yang Y; Hu Y; Yang R; Huang J; Liu Y; Wu Y; Li S; Ma C; Humphries F; Wang B; Wang X; Hu Z; Yang S
Cell Rep; 2022 Oct; 41(4):111553. PubMed ID: 36288704
[TBL] [Abstract][Full Text] [Related]
14. A recombinant oncolytic influenza virus expressing a PD-L1 antibody induces CD8
Sun F; Xu Y; Deng Z; Yang P
Int Immunopharmacol; 2023 Jul; 120():110323. PubMed ID: 37207446
[TBL] [Abstract][Full Text] [Related]
15. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.
Wu Q; Zhou W; Yin S; Zhou Y; Chen T; Qian J; Su R; Hong L; Lu H; Zhang F; Xie H; Zhou L; Zheng S
Hepatology; 2019 Jul; 70(1):198-214. PubMed ID: 30810243
[TBL] [Abstract][Full Text] [Related]
16. KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D.
Wang Y; Cao K
J Immunol Res; 2021; 2021():9965099. PubMed ID: 34307695
[TBL] [Abstract][Full Text] [Related]
17. PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity.
Guo S; Wang X; Zhou H; Gao Y; Wang P; Zhi H; Sun Y; Zhang Y; Gan J; Xiao Y; Ning S
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139065
[TBL] [Abstract][Full Text] [Related]
18. Bromo- and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma.
Liu C; Miao X; Wang Y; Wen L; Cheng X; Kong D; Zhao P; Song D; Wang X; Ding X; Xia H; Wang W; Sun Q; Gong W
Cancer Sci; 2020 Oct; 111(10):3503-3515. PubMed ID: 32726482
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.
Tan S; Guo X; Bei C; Zhang H; Li D; Zhu X; Tan H
BMC Cancer; 2022 Aug; 22(1):905. PubMed ID: 35986302
[TBL] [Abstract][Full Text] [Related]
20. TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma.
Yu J; Ling S; Hong J; Zhang L; Zhou W; Yin L; Xu S; Que Q; Wu Y; Zhan Q; Bao J; Xu N; Liu Y; Chen K; Wei X; Liu Z; Feng T; Zhou L; Xie H; Wang S; Liu J; Zheng S; Xu X
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]